Make no mistake, oligonucleotides are the next big thing in biologic therapies. Oligonucleotides have been in various stages of clinical development over the last 30 years, going through various modifications and adjustments as the technology matured to provide a viable therapeutic class. We have witnessed an explosive growth in Investigational New Drug (IND) applications for oligonucleotide-based therapies over the last decade. The therapeutic potential of oligonucleotides extends our scope of what we considered druggable molecular targets. This webinar describes the landscape of various oligonucleotide technologies for therapeutic application. Furthermore, it describes the application of mass spectrometry technology to solve some of the most pressing problems for the development of therapeutic oligonucleotides.
What will you learn?
- Gain understanding of the different classes of oligonucleotide therapies.
- Learn about the utility of mass spectrometry compared to ligand binding assays.
- Get an introduction to methods and best practices for oligonucleotide analysis.
- Learn about the application of mass spectrometry technology to answering preclinical challenges.
- See practical case studies in the quantitation and metabolism of oligonucleotide therapies.
Who may this interest?
- Scientists or lab directors already supporting oligonucleotide therapeutic development or those considering doing so.
Senior Research Fellow
Boehringer Ingelheim Pharmaceuticals (CT, USA)
Dr Chen obtained BS and MSc degrees from Nankai University, China, and a PhD degree in Organic Chemistry from the University of Mons, Belgium. After postdoctoral training at the Pacific Northwest National Laboratory in Washington (USA), he joined 3M Pharmaceuticals where he became a group leader responsible for metabolism and PK studies. He then joined Boehringer Ingelheim Pharmaceuticals to lead a group primarily responsible for metabolism and bioanalysis in support of drug development. In recent years, his group has been providing bioanalytical support to the development of therapeutic proteins and oligonucleotides as well as viral vector-based gene therapy. His group has developed a number of LC/MS assays for various biotherapeutic proteins such as nanobodies, Fabs, bispecifics and mAbs, siRNA and viral proteins. Dr Chen has more than 40 publications, and is an editor of peer-reviewed journals and an IQ consortium workgroup member.